Tumor microenvironment composition and related therapy in hepatocellular carcinoma
Z Li, Z Zhang, L Fang, J Zhao, Z Niu… - Journal of …, 2023 - Taylor & Francis
Globally, primary liver cancer is the third leading cause of cancer death, and hepatocellular
carcinoma (HCC) accounts for 75%–95%. The tumor microenvironment (TME), composed of …
carcinoma (HCC) accounts for 75%–95%. The tumor microenvironment (TME), composed of …
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies
SS Hoseini, NKV Cheung - Cancer letters, 2017 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide with an overall
survival rate of less than 15% in developed countries. Despite attempts at new therapeutic …
survival rate of less than 15% in developed countries. Despite attempts at new therapeutic …
Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases
C Rolin, J Zimmer, C Seguin-Devaux - Cellular & Molecular …, 2024 - nature.com
By binding to multiple antigens simultaneously, multispecific antibodies are expected to
substantially improve both the activity and long-term efficacy of antibody-based …
substantially improve both the activity and long-term efficacy of antibody-based …
In situ liver expression of HBsAg/CD3-bispecific antibodies for HBV immunotherapy
Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection,
necessitating new therapeutic approaches. The T cell response can clear HBV during acute …
necessitating new therapeutic approaches. The T cell response can clear HBV during acute …
[HTML][HTML] Advances in clinical research of hepatocellular carcinoma in China
ZY Tang - World Journal of Gastroenterology, 1998 - wjgnet.com
Based on the survey in 1990/1992, hepatocellular carcinoma (HCC) has become the
second cancer killer in China, the mortality rate was 20.37/100000 [1]. The etiological …
second cancer killer in China, the mortality rate was 20.37/100000 [1]. The etiological …
Means and methods for treating HBV infection and associated conditions
The present invention relates to a polypeptide comprising (a) a first set of six
complementarity determining regions (CDRs) configured to bind a first antigen; and (b)(ba) a …
complementarity determining regions (CDRs) configured to bind a first antigen; and (b)(ba) a …
[HTML][HTML] 慢性HBV 感染免疫治疗的研究进展
巫涛， 黄松， 刘煜 - Pharmacy Information, 2019 - hanspub.org
慢性乙型肝炎病毒感染是一个全球性的公共卫生问题. 近年来, 丙型肝炎治疗药物取得突破, 90%
以上丙肝病人在使用新型药物后实现临床治愈, 而慢性乙型肝炎的临床抗病毒治疗却依然依赖于 …
以上丙肝病人在使用新型药物后实现临床治愈, 而慢性乙型肝炎的临床抗病毒治疗却依然依赖于 …
Means and methods for treating HBV infection and associated conditions
The present invention relates to a polypeptide comprising (a) a first set of six
complementarity determining regions (CDRs) configured to bind a first antigen; and (b)(ba) a …
complementarity determining regions (CDRs) configured to bind a first antigen; and (b)(ba) a …
Establishment of hybridoma cell lines producing monoclonal antibodies against hepatitis B virus surface antigens (a, d, and r) and development of sensitive ELISA …
X Tang, X Zhang, H Xu - Hybridoma, 2001 - liebertpub.com
A new treble-coated enzyme-linked immunoadsorbent assay (ELISA) kit of detecting
Hepatitis B virus (HBV) surface antigen subtypes a, d and r (HBsAg-a,-d,-r) was developed …
Hepatitis B virus (HBV) surface antigen subtypes a, d and r (HBsAg-a,-d,-r) was developed …
Trispecific binding molecules for treating hbv infection and associated conditions
C07K16/2809—Immunoglobulins [IGs], eg monoclonal or polyclonal antibodies against
material from animals or humans against receptors, cell surface antigens or cell surface …
material from animals or humans against receptors, cell surface antigens or cell surface …